Latest Medical Cannabis News

Page 2 of 2
Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.
Ada Torres
Ada Torres
19 June 2025
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.
Victor Sage
Victor Sage
12 June 2025
Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.
Ada Torres
Ada Torres
13 Feb 2025
Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.
Victor Sage
Victor Sage
28 Jan 2025
Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.
Victor Sage
Victor Sage
23 Jan 2025